Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Financing › Details

Adcytherix–SEVERAL: investment, 202406 company launches with seed financing round €30m led by Pontivax Venture Capital

 

Period Period 2024-06-11
Organisations Money taker Adcytherix SAS
  Money source SEVERAL
Products Product antibody-drug conjugate (ADC)
  Product 2 venture capital
Person Person Nussbaum, Ran (Pontifax 200712 Managing Partner also CEO of Biomedix Incubator)
     

Adcytherix SAS. (6/11/24). "Press Release: Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates". Marseille.

> Vision is to establish a leading ADC developer to treat high unmet need diseases such as cancer.

> Founded by the team that founded and sold Emergence Therapeutics to Eli Lilly and Company.

> Seed round led by Pontifax and includes top-tier life science investors.


Adcytherix SAS today announced its incorporation and seed funding of € 30 million to develop novel antibody-drug-conjugates (ADCs) for the treatment of high unmet need diseases such as cancer.

The company was founded by Jack Elands and Pontifax Venture Capital with Xavier Preville and Carsten Dehning as co-founders. Adcytherix’ senior management team comprises Jack Elands (CEO), Carsten Dehning (CFO) and Xavier Preville (VP, Head of Research and Preclinical Development).

The seed round was led by Pontifax and supported by Pureos Bioventures, RA Capital Management and Dawn Biopharma (a platform controlled by KKR). Management also participated in the seed round.

Jack Elands, CEO of Adcytherix commented: “Our new company has as objective to meet the most urgent need of patients by developing a next generation of ADCs. We are excited that the top tier investors and business partners that supported us before joined us again to help us achieve our goals.”

Ran Nussbaum, Partner at Pontifax Venture Capital added: “We are excited to be part of this new adventure with a superb leadership that worked with us before. ADCs will play a major role in the future of oncology. The team that is leading the company and the syndicate that will support Adcytherix aim to build a well differentiated franchise in the field.”

As part of the seed round financing, Ran Nussbaum and Ohad Hammer of Pontifax, Ximing Ding of Pureos Bioventures, Iyona Rajkomar of Dawn Biopharma and Matthew Hammond of RA Capital Management joined the supervisory committee of Adcytherix.


---- ends ----


For more information please contact:

Adcytherix
Jack Elands, Chief Executive Officer
M: +33 6 38 35 70 08


About Adcytherix

Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer. The company is led by a seasoned management team and is supported by a network of world-leading experts in the field of ADC development. Adcytherix is backed by a syndicate of leading life science investors including Pontifax, Pureos Bioventures, RA Capital Management and Dawn Biopharma (a platform controlled by KKR). Adcytherix is based in Marseille, France. For more information please visit www.adcytherix.com

   
Record changed: 2024-06-17

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Adcytherix SAS


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px




» top